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Dear Editor,
We thank Dr. Salvadori and his col-
leagues for their interest in our work
[1] and the constructive comments. In
view of the evolving controversy
regarding the effects of hydrocorti-
sone therapy in sepsis during the
study period (January to December
2009), the use of hydrocortisone was
strictly reserved for patients with
septic shock requiring escalating
norepinephrine doses. This explains
why only one patient suffering from
septic shock received hydrocortisone
(continuous infusion of 200 mg/day)
at study enrollment. Unfortunately,
this precludes evaluation of the
influence of hydrocortisone on the
binary occurrence of adverse cardiac
events in our study population. At the
occurrence of an adverse cardiac
event, 15 of 21 septic shock patients
(71.4 %) received a continuous
hydrocortisone infusion at a median
(interquartile range, IQR) daily dose
of 192 (192–288) mg. The absolute
number of adverse cardiac events did
not differ between septic shock
patients with or without hydrocorti-
sone therapy [4 (2.5–6) versus 3
(2–7)] in both an unadjusted
(p = 0.64) and adjusted (p = 0.12)
model (model adjustment for Simpli-
fied Acute Physiology Score II, need
for renal replacement therapy, pres-
ence of chronic liver diseases).
Interestingly, however, patients on
hydrocortisone developed adverse
cardiac events at higher median
vasopressor load [0.48
(0.36–0.54) lg/kg/min] than patients
who did not receive hydrocortisone
[0.18 (0.06–0.43) lg/kg/min] in both
an unadjusted (p = 0.005) and
adjusted model (p = 0.006). The type
of adverse cardiac event had no
influence on this association
(p = 0.17 and p = 0.13, respec-
tively). Carrying the hypothesis of
Salvadori and colleagues on a poten-
tially protective effect of
hydrocortisone on the occurrence of
adverse cardiac events during cate-
cholamine vasopressor therapy
further, one may speculate that
hydrocortisone raised the individual
threshold at which catecholamine
vasopressors may induce adverse
cardiac events in our study patients
with septic shock. Taking the post -
hoc character of this analysis and the
low number of septic shock patients
developing adverse cardiac events
(n = 21) into consideration, these
data must be regarded as purely
hypothesis-generating. Further stud-
ies are, therefore, needed to evaluate
the influence of a hydrocortisone
therapy on the occurrence of adverse
(cardiac) events during catecholamine
vasopressor therapy in septic shock.
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